Larotrectinib is an oral targeted therapy specifically designed to treat cancers that harbor NTRK gene fusions. The NTRK gene fusion leads to the production of abnormal proteins that promote cancer cell growth. Larotrectinib works by inhibiting the activity of these proteins, thereby halting the progression of cancer.
